The evolving treatment landscape of higher-risk MDS
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Mohamed Elemary. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Myelodysplastic neoplasms (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, cytopenia, and morphologic dysplasia. Most cases of MDS are de novo, and a minority are post cytotoxic therapy About 30% of the cases will eventually progress to acute myeloid leukemia (AML), with a higher incidence among the higher-risk MDS group. MDS is a rare disorder with an overall incidence of 3.7-4.8/100,000; the rate increases with age.
Zitieren
APA
Elemary, M. (2022). The evolving treatment landscape of higher-risk MDS. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1317
Vancouver
Elemary M. The evolving treatment landscape of higher-risk MDS. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1317
BibTeX
@article{Elemary2022,
author = {Elemary, Mohamed},
title = {The evolving treatment landscape of higher-risk MDS},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1317}
}
EUVIMED